OakChart

BioVie Inc

BIVIHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

1.26-0.01 (-0.79%)
2026-11-12 02:48 CET
Market cap
13.51 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-22.59 USD m
Free cash flow, TTM
-18.91 USD m
EPS diluted, TTM
-2.89
P/E
-
Compare

Price

BIVI against its 20, 50 and 200-day averages
2050200
1.002.003.0063.2M126.4MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26BIVIclose 1.2620-day 1.3350-day 1.51200-day 1.521.2652w high52w low

66.8% under the 52-week high of 3.79 on 12 Aug 2026. 52-week low 0.82 on 6 Aug 2026. Last 15 sessions, 140.7% high to low

Volume 0.03× normal · the line is the 50-bar volume average

Profile

BIVI
52-week range, 15% of the way up
0.823.79

BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for neurological and neurodegenerative disorders, and liver disease. The company was founded on April 10, 2013 and is headquartered in Carson City, NV.

Employees13
IPOMay 05, 2014
Beta0.81
ATR, 14d0.20
Rel volume0.03
Short float5.70%
Insider own3.63%
Inst own19.24%

Snapshot

6 groups

Valuation

Index-
Market Cap13.51M
Enterprise Value6.03M
Income-22.59M
Sales0.00M
Book/sh0.75
Cash/sh0.72
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees13
IPOMay 05, 2014

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.68
P/C1.75
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio2.40
Current Ratio2.40
Debt/Eq0.04
LT Debt/Eq0.02
Option/ShortNo / Yes

Earnings

EPS (ttm)-2.89
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y72.98% 70.98%
Sales past 3/5Y- -
EPS Y/Y TTM67.39%
Sales Y/Y TTM-
EPS Q/Q31.12%
Sales Q/Q-
Earnings-
EPS/Sales Surpr.0.00% -

Ownership

Insider Own3.63%
Insider Trans6.36%
Inst Own19.24%
Inst Trans6.64%
ROA-119.34%
ROE-143.66%
ROIC-337.80%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-5.16%
SMA50-16.76%
SMA200-17.27%
Trades-

Technical

Shs Outstand10.72M
Shs Float10.34M
Short Float5.70%
Short Ratio0.13
Short Interest0.59M
52W High3.79 -66.75%
52W Low0.82 53.66%
Volatility10.91% 14.44%
ATR (14)0.20
RSI (14)45.19
Beta0.81
Rel Volume0.03
Avg Volume4.54M
Volume138,121

Performance

Perf Week-5.97%
Perf Month5.00%
Perf Quarter-19.23%
Perf Half Y-3.82%
Perf YTD8.62%
Perf Year-16.56%
Perf 3Y-99.62%
Perf 5Y-99.80%
Perf 10Y-99.97%
Recom1.00
Target Price5.51
Prev Close1.27
Price1.26
Change %-0.79%

Analyst ratings

latest 2 of 2
DateActionAnalystRating changeTargetImplied
Jul 22, 2022InitiatedCCantor FitzgeraldOverweight$7+455.6%
Jan 15, 2021InitiatedRB. Riley SecuritiesBuy$47+3,630.2%

Peers

Mkt cap
TickerCompanyMkt cap
ANVSAnnovis Bio Inc36.41M
ALZNAlzamend Neuro Inc6.32M
AVXLAnavex Life Sciences Corp98.26M
CGTXCognition Therapeutics Inc64.42M
CRVOCervoMed Inc26.78M
INMBINmune Bio Inc34.05M
ACOGAlpha Cognition Inc187.72M
ABOSAcumen Pharmaceuticals Inc16.64M
ATHEAlterity Therapeutics Ltd ADR44.12M
PMNProMIS Neurosciences Inc33.72M

Insider trading

4 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Palumbo Joseph MChief Medical OfficerAug 28 '26Buy2.164,84310,4616,036Aug 28 09:01 PM
Chappell Amy SuzonDirectorAug 28 '26Buy2.167271,570727Aug 28 09:01 PM
KIM JOANNE WENDYChief Financial OfficerAug 28 '26Buy2.182,5005,4503,441Aug 28 08:58 PM
DO CUONG VPresident & CEOAug 27 '26Buy2.0815,21031,63716,117Aug 28 08:57 PM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q12025-12-03-0.980-0.980-0.9840.000.001
2025Q42025-09-03-1.820-1.820-1.8230.000.001
2025Q32025-05-28-1.510-1.500-1.5070.000.001
2025Q22025-02-26-4.600--4.5540.00--
2024Q32024-05-10-20.000--19.9870.00--
2024Q12023-11-29-29.000-29.000-29.1500.000.002
2023Q42023-09-26-25.000-25.080-25.0130.000.002
2023Q32023-05-12-43.000-35.500-42.5790.000.002
2023Q12023-02-13-33.320--38.2760.00-2
2023Q22023-02-10-50.170-25.250-50.3290.000.004
2022Q32022-11-04-28.000-42.330-28.1810.000.003
2022Q42022-10-14-36.000--32.3760.00-2
2022Q22022-09-27-28.330-31.000-21.6900.000.001
2022Q12021-12-01-23.000-23.000-23.3590.000.001
2021Q42021-11-29-822--588.950.00-1
2021Q32021-08-04-22.000--21.501---

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-1,482-718-1,4820.00-
2022FY-110-114-105.770.000.00
2023FY-155-154.86-154.710.000.00
2024FY-73.000-101-73.0480.00-0.60
2025FY-12.120-12.120-0.000.00
2026FY-1.190-1.190-2.102.10
2027FY--0.630---
2028FY--0.570---
2029FY--0.550---
2030FY--0.530---

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2027FYS2025-10-311000.000.000.00
2027FYS2025-10-301000.000.000.00
2027FYS2025-10-291000.000.000.00
2027FYS2025-10-281000.000.000.00
2027FYS2025-10-271000.000.000.00
2027FYS2025-10-261000.000.000.00
2027FYS2025-10-251000.000.000.00
2027FYS2025-10-241000.000.000.00
2027FYS2025-10-231000.000.000.00
2027FYS2025-10-221000.000.000.00
2027FYS2025-10-211000.000.000.00
2027FYS2025-10-201000.000.000.00
2027FYS2025-10-191000.000.000.00
2027FYS2025-10-181000.000.000.00

Estimate history

EPS, annual-375-98.125-685.178-1482.264-105.765-154.712-73.048-12.124-3.052-2.8912
Period201820192020202120222023202420252026TTM
EPS, quarterly-6.997-4.554-1.507-1.823-0.984-0.766-0.699-0.749-0.678
PeriodQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26Q1 '27
Sales, annual0000000000
Period201820192020202120222023202420252026TTM
Sales, quarterly000000000
PeriodQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26Q1 '27
Shares, annual0.0080.0410.0520.2230.250.3640.6191.9147.5438.691
Period201820192020202120222023202420252026MRQ
Shares, quarterly0.7961.8451.8521.9147.5377.5417.5427.5438.691
PeriodQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26Q1 '27

Income statement, annual

Currency USD, millions
MetricTTM2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.120.180.230.230.270.240.230.230.23
Gross Profit-0.12-0.18-0.23-0.23-0.27-0.24-0.23-0.23-0.23
Selling, General and Administrative Excl. Other22.9022.4717.8431.9644.8127.02137.822.462.27
Research and Development14.3613.969.2723.1033.3017.26133.191.151.01
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-23.02-22.65-18.07-32.18-45.08-27.25-138.05-2.69-2.50
Interest Expense0.020.020.332.894.302.160.564.770.00
Unusual Expense0.000.00-0.00-1.821.44-3.29-8.349.21-0.05
Net Income Before Taxes-22.59-22.07-17.54-32.12-50.26-26.08-130.25-16.68-2.44
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-22.59-22.07-17.54-32.12-50.26-26.08-130.25-16.68-2.44
Net Income From Continuing Operations-22.59-22.07-17.54-32.12-50.26-26.08-130.25-16.68-2.44
Net Income-22.59-22.12-17.91-33.01-50.26-26.08-183.85-33.78-2.49
EPS (Recurring)-2.73-3.05-12.13-75.87-151.61-115.10-1,529.35-554.37-99.58
EPS (Basic, Before Extraordinaries)-2.89-3.05-12.12-73.05-154.71-105.77-1,482.26-685.18-98.12
EPS (Diluted)-2.89-3.05-12.12-73.05-154.71-105.77-1,482.26-685.18-98.12
EBITDA-22.90-22.47-17.84-31.96-44.81-27.02-137.82-2.46-2.27
Non-Operating Income (Expense)0.440.600.851.140.560.040.020.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.542.871.202.824.205.813.020.020.06
Shares Outstanding8.697.541.910.620.360.250.220.050.04
Market Capitalization13.5113.6217.7124.42157.0136.23378.5572.8633.23

Income statement, quarterly

Currency USD, millions
Metric2027Q12026Q42026Q32026Q22026Q12025Q42025Q32025Q2
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.010.060.060.060.060.060.06
Gross Profit0.00-0.01-0.06-0.06-0.06-0.06-0.06-0.06
Selling, General and Administrative Excl. Other5.655.715.336.205.233.612.937.24
Research and Development3.343.583.184.272.941.221.344.70
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-5.65-5.72-5.39-6.26-5.28-3.66-2.99-7.29
Interest Expense0.000.000.010.010.000.000.000.07
Unusual Expense0.000.000.000.000.000.00-0.010.01
Net Income Before Taxes-5.61-5.65-5.27-6.07-5.09-3.49-2.79-7.11
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-5.61-5.65-5.27-6.07-5.09-3.49-2.79-7.11
Net Income From Continuing Operations-5.61-5.65-5.27-6.07-5.09-3.49-2.79-7.11
Net Income-5.61-5.65-5.27-6.07-5.13-3.49-2.79-7.16
EPS (Recurring)-0.68-0.75-0.70-0.77-0.98-1.82-1.51-4.55
EPS (Basic, Before Extraordinaries)-0.68-0.75-0.70-0.77-0.98-1.82-1.51-4.55
EPS (Diluted)-0.68-0.75-0.70-0.77-0.98-1.82-1.51-4.55
EBITDA-5.65-5.71-5.33-6.20-5.23-3.61-2.93-7.24
Non-Operating Income (Expense)0.050.080.120.200.200.180.200.25
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.200.311.610.410.27-0.560.680.65
Shares Outstanding8.697.547.547.547.541.911.851.85
Market Capitalization13.5114.6310.568.7514.3117.7118.1536.90

Balance sheet, annual

Currency USD, millions
Metric2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments8.9817.5423.8433.9418.644.510.040.340.05
Short Term Receivables2.152.100.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets2.511.050.200.100.140.090.380.330.00
Total Current Assets13.6420.7024.0534.0418.784.610.410.670.05
Net Property, Plant & Equipment0.260.340.410.080.120.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets0.350.520.750.981.211.441.671.902.13
Other Assets0.000.000.000.000.000.000.000.000.00
Total Assets14.2521.5625.2135.1020.116.052.082.572.18
Short Term Debt Incl. Current Port. of LT Debt0.090.075.769.150.040.000.800.000.00
Accounts Payable0.000.000.000.000.001.001.260.000.00
Other Current Liabilities3.702.203.595.344.130.0021.460.441.24
Total Current Liabilities3.802.279.3514.494.171.0023.520.441.24
Long Term Debt0.180.280.355.2712.230.000.060.000.83
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.050.000.000.000.00
Total Liabilities3.982.559.7019.7616.441.0023.580.442.06
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity10.2719.0115.5115.343.675.05-21.502.130.11
Total Shareholders Equity10.2719.0115.5115.343.675.05-21.502.130.11
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity10.2719.0115.5115.343.675.05-21.502.130.11
Total Liabilities & Stockholders Equity14.2521.5625.2135.1020.116.052.082.572.18
Book Value Per Share1.369.9325.0542.1114.6922.61-413.0952.5114.11
Tangible Book Value Per Share1.329.6623.8339.419.8416.16-445.195.68-256.15
Full-Time Employees1313141813----
Price to Book Ratio1.690.931.2910.249.8774.96-3.3911.939.46
Return on Assets-123.27-75.01-106.51-182.02-199.41-3,203.92-716.00-102.92-106.31
Return on Equity-150.76-101.64-208.26-528.70-598.18---218.03-380.46
Return on Invested Capital-211.13-90.95-202.58-243.84-164.08-2,579.03--114.71-257.50
Quick Ratio3.599.102.572.354.504.620.021.520.04
Current Ratio3.599.102.572.354.504.620.021.520.04

Cash flow, annual

Currency USD, millions
MetricTTM2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-22.59-22.07-17.54-32.12-50.26-26.08-130.25-16.68-2.44
Depreciation0.120.180.230.230.270.240.230.230.23
Other Funds (Non Cash)2.622.952.684.0310.014.11119.5514.050.17
Funds from Operations-19.85-18.94-14.63-27.86-39.98-21.74-10.47-2.40-2.05
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital0.95-0.08-4.40-0.09-0.272.750.020.77-0.45
Cash from Operating Activities-18.91-19.02-19.03-27.95-40.25-18.99-10.45-1.63-2.50
Capital Expenditures0.000.000.000.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.0014.53-14.300.000.000.000.00
Purchase of Investments0.000.000.000.00-14.300.000.000.000.00
Sale Or Maturity of Investments0.000.000.0014.530.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities0.000.000.0014.53-14.300.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock1.6610.4618.5827.8055.3718.5116.310.003.04
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock1.6610.4618.5827.8055.3718.5116.310.003.04
Proceedsfrom Stock Options0.1410.4615.6727.8055.3718.5115.630.003.04
Issuance or Reduction of Debt, Net0.000.00-5.85-10.000.0014.61-1.391.33-0.24
Change in Long Term Debt0.000.00-5.85-10.000.0014.61-1.820.06-0.24
Issuance of Long Term Debt0.000.000.000.000.0014.610.000.060.00
Reduction of Long Term Debt0.000.00-5.85-10.000.000.00-1.820.00-0.24
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities1.6610.4612.7317.8055.3733.1214.931.332.80
Net Change in Cash-17.25-8.57-6.304.380.8214.134.47-0.300.29
Free Cash Flow-18.91-19.02-19.03-27.95-40.25-18.99-10.45-1.63-2.50
Preferred Dividends (Cash Flow)----0.000.00---
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2027Q12026Q42026Q32026Q22026Q12025Q4
Cash & Short Term Investments7.738.9813.1020.5424.9817.54
Short Term Receivables0.222.152.170.200.182.10
Inventories0.000.000.000.000.000.00
Other Current Assets2.502.511.611.060.871.05
Total Current Assets10.4513.6416.8821.7926.0320.70
Net Property, Plant & Equipment0.240.260.280.300.320.34
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.350.350.350.410.470.52
Other Assets0.000.000.000.000.000.00
Total Assets11.0414.2517.5122.5026.8221.56
Short Term Debt Incl. Current Port. of LT Debt0.100.090.080.080.080.07
Accounts Payable0.000.000.000.000.000.00
Other Current Liabilities4.253.701.612.921.572.20
Total Current Liabilities4.353.801.693.011.642.27
Long Term Debt0.160.180.210.230.250.28
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities4.513.981.913.241.902.55
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity6.5310.2715.6119.2724.9219.01
Total Shareholders Equity6.5310.2715.6119.2724.9219.01
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity6.5310.2715.6119.2724.9219.01
Total Liabilities & Stockholders Equity11.0414.2517.5122.5026.8221.56
Book Value Per Share0.751.362.072.553.319.93
Tangible Book Value Per Share0.711.322.022.503.249.66
Full-Time Employees-13---13
Price to Book Ratio1.680.940.550.350.190.93
Return on Assets-119.34-123.27-94.45-72.35-76.90-75.01
Return on Equity-143.66-150.76-106.43-80.74-94.79-101.64
Return on Invested Capital-83.81-54.00-33.31-31.13-20.21-18.09
Quick Ratio2.403.599.977.2515.839.10
Current Ratio2.403.599.977.2515.839.10

Cash flow, quarterly

Currency USD, millions
Metric2027Q12026Q42026Q32026Q22026Q12025Q4
Net Income-5.61-5.65-5.27-6.07-5.09-3.49
Depreciation0.000.010.060.060.060.06
Other Funds (Non Cash)0.220.331.630.430.560.70
Funds from Operations-5.38-5.31-3.58-5.58-4.47-2.73
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital2.481.19-3.861.141.45-2.88
Cash from Operating Activities-2.91-4.12-7.44-4.44-3.02-5.61
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.00-----
Change in Capital Stock1.660.000.000.0010.460.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock1.660.000.000.0010.460.00
Proceedsfrom Stock Options0.140.000.000.0010.460.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities1.660.000.000.0010.460.00
Net Change in Cash-1.24-4.12-7.44-4.447.43-5.61
Free Cash Flow-2.91-4.12-7.44-4.44-3.02-5.61

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-307.17%0.6M8.2M4.52M
2026-10-156.62%0.5M8.2M4.52M
2026-09-3010.11%0.8M8.2M4.60M
2026-09-1512.91%1.0M8.1M4.66M
2026-08-3111.02%0.9M8.0M4.54M
2026-08-1415.58%1.3M8.1M2.53M
2026-07-3111.13%0.8M7.2M166.80K
2026-07-159.13%0.7M7.2M150.05K
2026-06-306.25%0.4M7.2M116.10K
2026-06-154.18%0.3M7.2M91.83K
2026-05-292.63%0.2M7.2M81.87K
2026-05-152.64%0.2M7.2M83.90K
2026-04-302.46%0.2M7.2M84.75K
2026-04-151.80%0.1M7.2M85.27K
2026-03-312.14%0.2M7.2M95.13K
2026-03-132.12%0.2M7.2M106.78K
2026-02-271.97%0.1M7.2M105.21K
2026-02-132.47%0.2M7.2M99.40K
2026-01-302.71%0.2M7.2M96.67K
2026-01-152.13%0.2M7.2M98.79K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-108-KCurrent report2026-11-10SEC
2026-11-06SCHEDULE 13G/ASEC
2026-11-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-068-KCurrent report2026-11-03SEC
2026-11-05424B5SEC
2026-11-05424B5SEC
2026-11-04424B5SEC
2026-09-28DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-09-28SEC
2026-09-148-KCurrent report2026-09-11SEC
2026-09-14424B5SEC
2026-09-03SCHEDULE 13GSEC
2026-08-284Statement of changes in beneficial ownership of securities2026-08-28SEC
2026-08-284Statement of changes in beneficial ownership of securities2026-08-28SEC
2026-08-284Statement of changes in beneficial ownership of securities2026-08-28SEC
2026-08-284Statement of changes in beneficial ownership of securities2026-08-27SEC
2026-08-19SCHEDULE 13GSEC
2026-08-14S-1/ASEC
2026-08-1310-KAnnual report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-07FWPFiling under Securities Act Rule 163/433 of free writing prospectuses.SEC
2026-08-07SCHEDULE 13G/ASEC
2026-08-07SCHEDULE 13GSEC
2026-08-06FWPFiling under Securities Act Rule 163/433 of free writing prospectuses.SEC
2026-08-06FWPFiling under Securities Act Rule 163/433 of free writing prospectuses.SEC
2026-08-06S-1/ASEC
2026-08-068-KCurrent report2026-08-06SEC
2026-07-31S-1/ASEC
2026-07-17S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-06-29EFFECTEffectiveness filing by commission orderSEC
2026-06-18S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-06-11DRSSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-0849.12K400
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
MORGAN STANLEY8.03%
Diametric Capital, LP3.40%
RENAISSANCE TECHNOLOGIES LLC1.70%
CITADEL ADVISORS LLC1.27%
ACADIAN ASSET MANAGEMENT LLC0.95%
VANGUARD CAPITAL MANAGEMENT LLC0.94%
GEODE CAPITAL MANAGEMENT, LLC0.89%
PHILADELPHIA TRUST CO0.59%
VANGUARD FIDUCIARY TRUST CO0.50%
JANE STREET GROUP, LLC0.48%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND0.94%
Fidelity Extended Market Index Fund0.46%
Fidelity Series Total Market Index Fund0.13%
Fidelity Nasdaq Composite Index Fund0.09%
Fidelity Total Market Index Fund0.03%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. BIVI. Cached 15 minutes.